SGM 101

Drug Profile

SGM 101

Latest Information Update: 30 Nov 2016

Price : $50

At a glance

  • Originator SurgiMAb
  • Developer Centre for Human Drug Research; Institut du Cancer de Montpellier - Val d'Aurelle; Leiden University Medical Center; SurgiMAb
  • Class Antineoplastics; Immunoconjugates
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Colorectal cancer; Pancreatic cancer; Rectal cancer
  • Phase I Breast cancer; Gastric cancer

Most Recent Events

  • 13 May 2016 SurgiMab initiates enrolment in a phase I trial for Breast cancer (IV)
  • 05 Feb 2016 SurgiMab initiates enrolment in a phase I trial for Rectal cancer and Pancreatic cacner (Diagnosis) in Netherlands (IV) (EudraCT2015-003281-88)
  • 01 Jan 2016 Phase-I/II clinical trials in Colorectal cancer, Pancreatic cancer and Rectal cancer (Diagnosis) in Netherlands (IV) (NCT02973672)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top